Skip to NavigationSkip to content

Cobra Biologics appoints CSO

Published on: 08/05/14

Contract manufacturing organisation Cobra Biologics has hired Dr Daniel Smith as its chief scientific officer.

Smith has spent the last four years with the bioProcessUK team at the HealthTech & Medicines Knowledge Transfer Network (KTN), implementing its innovation agenda for biologics bioprocessing in the UK as a Knowledge Transfer manager. 

He also worked on a number of projects enhancing industrial and academic collaboration as well as innovation in bioprocessing as a senior technologist.

Prior to work at the KTN, Smith gained his industrial experience at Cobra in a variety of roles progressing from senior scientist to commercial scientific development manager.

Peter Coleman, chief executive at Cobra Biologics says: “This is a significant appointment for Cobra and I am personally very pleased that Dan has decided to return to Cobra as our new CSO. He has a tremendous enthusiasm for science and its application in our industry and from working with him previously, I firmly believe he has experience and ability to further establish Cobra as a leading scientific organisation.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches